The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s showing significant promise in clinical trials for addressing obesity. Unlike some existing weight loss solutions, retatrutide appears to deliver a more substantial decrease in body mass and enhance metabolic health, particularl… Read More